LentiFlash™ particles carrying CRISPR-Cas9 technology show promising results to disrupt targeted genes in several therapeutic fields!
LentiFlash™-CRISPR-Cas9 particles allow efficient KO of genes of interest in human primary T cells for multiple applications such as:
Click here to unsuscribe from the mailing list